Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $25,400.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the transaction, the president now owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. The trade was a 0.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total value of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.82, for a total value of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Performance

Shares of GYRE traded up $0.21 during midday trading on Monday, reaching $12.66. The stock had a trading volume of 88,873 shares, compared to its average volume of 75,660. The firm has a 50 day simple moving average of $12.71 and a 200-day simple moving average of $12.66. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $27.45.

Institutional Trading of Gyre Therapeutics

Hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. grew its stake in Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after buying an additional 90,557 shares during the last quarter. Geode Capital Management LLC lifted its position in Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after acquiring an additional 43,840 shares during the last quarter. Advantage Alpha Capital Partners LP bought a new stake in shares of Gyre Therapeutics during the third quarter worth approximately $334,000. WINTON GROUP Ltd bought a new position in shares of Gyre Therapeutics during the second quarter worth approximately $220,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Gyre Therapeutics during the second quarter worth approximately $218,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.